Neurimmune is a Swiss biotechnology company specializing in the development of antibody therapeutics for the treatment of neurodegenerative diseases. Founded in 2007 and headquartered in Schlieren, Zurich, Switzerland, Neurimmune has pioneered a proprietary technology platform for identifying naturally occurring human antibodies with therapeutic potential[1].
The company is known for its groundbreaking work on alpha-synuclein and tau antibodies, as well as its role in the development of aducanumab (Aduhelm), a monoclonal antibody targeting amyloid-beta plaques in Alzheimer's disease[2].
| Attribute | Details |
|---|---|
| Founded | 2007 |
| Headquarters | Schlieren, Zurich, Switzerland |
| Focus | Antibody therapeutics for neurodegeneration |
| Technology | Human antibody discovery platform |
Neurimmune's pipeline focuses on several key targets in neurodegenerative diseases:
NI-202: Anti-alpha-synuclein antibody program for Parkinson's disease. Aims to target and clear toxic alpha-synuclein aggregates that are characteristic of PD pathology.
NI-203: Next-generation alpha-synuclein antibody with enhanced brain penetration
AP-101: Anti-amyloid antibody for ALS (amyotrophic lateral sclerosis)
ALXN2220 (Cliramidug): Anti-ATTR program for transthyretin amyloidosis (in partnership with Alexion)
NI-301: Tau antibody program for Alzheimer's disease
Neurimmune's antibody discovery platform is based on:
This approach has yielded several clinical-stage antibodies targeting key proteins in neurodegeneration.
Neurimmune maintains a strong scientific advisory board including leading researchers in neurodegeneration, immunology, and antibody therapeutics.
Neurimmune represents a key player in the neurodegenerative disease antibody therapeutics space. Their approach of identifying naturally occurring human antibodies provides several advantages:
The company's focus on multiple protein targets (alpha-synuclein, tau, amyloid-beta) positions it at the forefront of multi-target approaches to treating Alzheimer's and Parkinson's diseases[4].